🧠 At a Glance
Onconetix, Inc. (OTC: ONCO) just dropped its Form 10-K for FY2024, and honestly — it’s the biotech equivalent of submitting your resume to NASA after failing 10th-grade physics.
- 💰 Revenue: $0
- 🔥 Annual Loss: $3.84 million
- 💸 Cash Left: $12,000 — enough for 6 months of rent or one failed conference trip
- 🧪 Drug Pipeline: One molecule, zero trials, infinite optimism
- 📉 Stock Price: $0.12 and falling faster than investor patience
- 🚑 Auditor’s Mood: “Going Concern? Bro, it’s already gone.”
If biotech was a religion, Onconetix is that guy knocking on doors asking for funding in the name of science… and offering prayers instead of data.
🧬 The Company: Onconetix, Inc.
Previously known as Sophiris Bio, this is a cancer drug company with:
- One legacy molecule (Topsalysin)
- Zero trials currently running
- Zero approvals
- Zero employees with anything new to say
They rebranded as Onconetix to sound edgy and oncology-centric. But let’s be real — this is a shell with a fancy name and a
